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ABSTRACT 
Research Study to Reduce Opioid Medication Use in Chronic Pain 
Patients by Adding Memantine: A Pilot Study 
Adam J. Bertino, B.S. 
Masters in Biomedical Sciences, July 2017 
Philadelphia College of Osteopathic Medicine 
Frederick J. Goldstein, PhD, Thesis Adviser 
 
An investigational clinical research pilot study is being conducted at a nursing 
facility and an academic primary care office to evaluate memantine as an adjunct to 
opioid therapy for treatment of chronic pain. Memantine can be beneficial in reducing 
pain because it is an N-methyl-D-aspartate receptor (NMDAr) antagonist with a pivotal 
action in the hippocampus: it initiates long-term potentiation in the anterior cingulate 
cortex and forebrain. These areas of action have a high probability for reducing the 
affective quality of pain.  
This open-label, non-randomized pilot study is designed to observe any effects 
which may occur during addition of memantine to the therapeutic regimen of nursing 
home patients and office patients who take daily opioids (oxycodone, 
oxycodone/acetaminophen combination or hydromorphone) on an as-needed basis (prn) 
for chronic pain. The objective is to gauge, preliminarily, whether patients benefit from 
using memantine as an adjunct to their daily oxycodone/acetaminophen or 
hydromorphone treatment by increased analgesia, a reduction of opioid used, and 
increased bowel movements. 
iv 
 
 
 
Memantine efficacy was assessed using pain diaries where patients recorded on a 
daily basis the amount of opioid used, pain scores (from ‗0‘ [no pain] to ‗10‘ [worst pain 
ever]), and number of bowel movements. Data are collected for six weeks; initially a two-
week, no-memantine observation period, followed by a four-week treatment phase. 
Collected data are then analyzed.  
With the first patient to complete the study, a trend of decreased pain scores over 
the six-week study was observed. There was also an indication of decreased opioid use 
but may be due to inconsistencies; bowel movements fluctuated and did not show a trend. 
The second patient showed trends of a decreased pain score with a decrease in opioid 
dosage over the course of the study and slightly lower bowel movements per week. 
This pilot study presented insight to the plausible use of memantine as an adjunct 
to treat chronic pain patients. Although the number of patients that participated in this 
pilot was small, the trends observed may help to launch this type of study into a larger 
scale. Thus, these initial data present insight to the plausible use of memantine as an 
adjunct to treat chronic non-malignant pain patients who take an opioid daily. 
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Chapter 1 
INTRODUCTION 
 
Approximately 20 percent of adults live with moderate to severe chronic pain that 
lasts for six months or longer [15].  Opioids may be considered to be the first drug of 
choice to combat severe chronic pain; over the past decade there has been an exponential 
increase in opioid prescriptions in the United States, Australia, and Europe [15]. Typical 
opioids available to treat chronic pain include morphine, codeine, oxycodone, fentanyl, 
and buprenorphine that are administered in multiple forms, e.g., tablet, skin patch, 
sublingual liquid.  For individuals with persistent severe pain (―high impact pain‖), high 
levels of opioid dosage result in improved analgesia but also increase the frequency 
and/or intensity of adverse effects; these reactions include sedation, impaired cognitive 
function, depression, constipation, and bladder dysfunction [15].  Endocrine dysfunction 
can develop such as hypogonadism/hypotestosteronism caused by central depression of 
hypothalamic secretion [9].  Furthermore, despite an increase in dosage, it is common for 
opioids to become ineffective over time due to tolerance, which, consequently, increases 
adverse effects. There is a risk that the patient may abuse, misuse or divert these 
medications. According to the American Society of Addiction Medicine, ―Of the 21.5 
million Americans 12 or older that had a substance use disorder in 2014, 1.9 million had 
a substance use disorder involving prescription pain relievers and 586,000 had a 
substance use disorder involving heroin‖ [1]. Patients develop tolerance to many 
pharmacological properties such as sedation, respiratory depression and nausea but not to 
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gastrointestinal hypomotility. With increased opioid dosage, this adverse effect becomes 
a major problem in the life of a chronic pain patient which can decrease the quality of 
living. 
Pain can be described as a dynamic phenomenon, influenced by various 
mechanisms of excitatory and inhibitory control. Gender can factor into the amount of 
pain a patient experiences, due to varied levels of hormones in each system that are 
produced by the ovaries and testes. The different amount of hormones produced by each 
sex may have a direct impact on the perception of pain. Estradiol which is produced by 
the testes and more so in ovaries, can potentiate glutamate binding to NMDAr [18].  
A retrospective cohort study was performed to determine if a gender difference 
exists in the incidence of severe postoperative pain episodes. Pain scores were collected 
from various types of non-ambulatory surgical procedures (e.g. coronary artery bypass 
graft, heart valve procedures, and laminectomy) using the Numeric Rating Scale (NRS), 
which is an 11 point scale (0-10) with 0 being no pain at all and 10 being the worst pain 
ever experienced. In addition, the incidence of severe pain events was determined by 
employing a SPE (Sudden Painful Events) scale; which is how many episodes of sudden-
onset pain were experienced post-surgery. Evaluation of 333,000 pain scores between 
males and females, in similar procedural categorizations, resulted in a statistical 
difference. At post-operative day (POD) 1, the female averaged pain score was 4.20 with 
males at 3.98 (mean difference 0.22, 99% Cl 0.16-0.28, p<0.0001). At POD 5, the female 
average pain score was 4.11, and male average of 3.74 (mean difference 0.36, 99% Cl 
0.33-0.40, p<0.0001). With these data, it was concluded that, on average, females report 
higher numeric pain intensity ratings within a clinical environment and that they 
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experience a greater incidence of SPEs on POD 1. Also, through the NRS pain scores, 
females had increasing pain through POD 5, which shows that males had a quicker 
decrease in pain than females [24]. 
A survey was performed to determine differences between females and males 
during a painful stimulus by studying the relationship between gonadal hormones and the 
central nervous system. When considering the epidemiology of sex differences in pain, 
researchers found that females tend to report more severe pain and longer lasting pain 
than their male counterparts with similar disease processes such as irritable bowel 
syndrome, chronic pelvic pain and interstitial cystitis. Females also have a more frequent 
prevalence of pain when the pain is related to musculoskeletal, visceral origin or 
autoimmune diseases like lupus and rheumatoid arthritis. Also, females are more likely to 
visit a physician when experiencing pain and use significantly more pain-relieving 
medications, even when the frequency and severity of pain was equated for the sexes. To 
explain this finding, there was a consideration of gonadal steroid hormones produced by 
the ovaries and testes. The testes mainly produce androgens, testosterone, and 
dihydrotestosterone, whereas, the ovaries mainly produce estrogens and progestin. The 
precise roles of these biological substances in relation to pain are not yet well understood. 
Effects on pain and analgesia were first thought to be caused by release of gonadal 
hormones and are possibly due to de novo hormone synthesis in the affected tissues. The 
hypothesis that gonadal hormones can affect sensitivity to pain when an organism is 
developing and throughout adulthood has also been tested in this research by examining 
the endogenous opioid neurotransmitters and μ opioid receptors. Females and males 
differ in their concentration of μ opioid receptors, which may be due to age and the 
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amount of circulating gonadal steroids [18]. According to the researchers, in various 
human experiments, females are generally found to have a greater amount of μ opioid 
receptors in the periaqueductal gray (PAG), including descending projections to the 
rostral ventral medulla (RVM) and dorsal horn of the spinal cord, when measured 
with positron emission tomography. Researchers used the individual gender role 
expectations of pain (GREP) on experimental pain report and VAS to rate pain intensity. 
Males showed significantly higher pain endurance than females with similar disease, but 
females indicated a greater willingness to report pain. These investigators performed 
another study to assess the difference between genders regarding response to 
interdisciplinary chronic pain management. Females were found to have a greater benefit 
from pain management than males, although the investigators did not discuss why this 
occurred. Interdisciplinary chronic pain management is a series of therapies relating to 
pain and distress at three time points (immediately prior, on completion, and three 
months following intervention). This includes PT/OT, psychology, pharmacology, ect. 
Also reported was greater morphine analgesia in men than women, and women needed 
about 30% more morphine to have the same level of analgesia as men after surgical 
removal of the third molar tooth [18].  
  In a study comparing effects of patient-controlled analgesia (PCA) with morphine 
between women and men from trauma-related pain (not specified), as the PCA duration 
was increased, there was also a positive correlation in the morphine effect between the 
sexes, the morphine effect also increased (n=11, 95% c.i. 0.01-0.69, p=0.047). When 
considering μ opioid receptors in experimental pain studies, women had a larger decrease 
of painful stimulus by sensory neurons while taking opioids when compared to men, as 
5 
 
 
 
seen from performing a sensitivity analysis (n=11, effect size=0.36, 95% c.i. 0.17-0.56, 
p=0.003). Although there are no pharmacokinetic gender differences, morphine was more 
effective in women at lower dosages, but had a slower onset of action. Researchers are 
still uncertain about the reasoning behind the latter effect, but it may be explained by 
slower progression though the blood-brain barrier or to the sex differences in receptor - 
ligand kinetics. Although there is greater morphine effectiveness in women once the 
relatively delayed effect is appreciated, men exhibit an analgesic greater effect directly 
after injection [17].  
To improve safety, efficacy and reduce the potential for addiction and abuse, 
chronic pain can be treated through a variety of different categories of non-opioid 
medications instead of, or in conjunction with, opioids. Medications that can be used to 
complement opioids include acetaminophen, non-steroidal anti-inflammatory drugs 
(NSAIDs), antidepressants, anticonvulsants, and benzodiazepines. The most common 
non-opioid medications used to treat chronic pain that can result from trauma, arthritis, 
surgery, or cancer are acetaminophen and NSAIDs; they are effective when taken alone 
or in combination with opioids. Acetaminophen is a non-salicylate that has analgesic and 
antipyretic effects similar to aspirin.  Although acetaminophen does not irritate the gastric 
mucosa, use of this drug must be monitored in patients who consume alcohol daily and/or 
have underlying liver disease due to the fact that they can develop acetaminophen-
induced hepatotoxicity. The disadvantage  of NSAIDs is that they have a ceiling effect, 
i.e., once a therapeutic ceiling level has been established, any further increases in  dosage  
will increase side effects without  additional analgesia. Physicians must be cautious when 
prescribing NSAIDs in conjunction with opioid therapy, especially in elderly patients 
6 
 
 
 
with certain medical co-morbidities as they can cause gastrointestinal (GI) bleeding, 
impairment in renal function and, most importantly, have been linkded to cardiovascular 
events. The most common side effects are GI consisting of anorexia, dyspepsia, nausea, 
abdominal pain and diarrhea. Tricyclic antidepressants (TCAs) when administered with 
opioids, improve analgesia. Patients who received opioid medications with intramuscular 
amitriptyline after a cholecystectomy [6] or cesarean section [25] showed a reduction in 
the amount of opioid needed to improve analgesia. TCA analgesic effects are shown to 
work in as little as 24 hours of use, while antidepressant actions can take up to a week or 
more to appear [11]. It is believed that the mechanisms of TCAs are related to blocking 
serotonin and norepinephrine reuptake, and stabilizing nerve membranes [11]. 
Anticonvulsants such as gabapentin and pregabalin can be used successfully when 
treating pain if opioid medication therapy is not effective, e.g., in diabetic neuropathy or 
trigeminal neuralgia. This is due the main actions of anticonvulsants that decrease 
voltage-gated calcium or sodium channels, and improved performance of the gamma-
aminobutyric acid (GABA) inhibitory system [11].  
Patients in chronic pain who are on opioids can experience anxiety and mood 
disorders. Adding benzodiazepines in this situation can be useful; however, it can 
increase the chance of respiratory depression, and also misuse or addiction [11].  
A recent study was conducted in patients with post-operative stump pain after 
major lower limb amputation. This research involved 198 patients over a four-year 
period; 102 received a perineural catheter and were compared to 96 patients who did not 
receive the perineural catheter. The catheter was used to bathe the nerve endings with 
analgesic medications. By multiple regression analyses, perineural catheter use was 
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shown to lower cumulative post-op opioid consumption over the first 72 hours. 
Researchers compared the amount of morphine needed between the two groups in the 
first 72 hours post-op, along with the post-operative pain intensity within the first 24 
hours. Analgesic medications were converted to morphine equivalents and patients who 
received a perineural catheter required less cumulative post-operative opioid medication 
over the first 72 hours (catheter 81.23 ± 90.77 mL/hr vs. non-catheter 134.51 ± 145.49 
mL/hr, p = 0.03), leading to a lower adverse effect rate of sedation and nausea, leading to 
a greater quality of life for the patients [2]. 
Other effective adjuncts to opioid therapy for the treatment of chronic pain are N-
methyl-D-aspartate receptor (NMDAr) antagonists. Ketamine is such an agent but has 
serious adverse drug reactions including dysphoria and hallucinations which limit clinical 
use (Parsons et al. 2013). Memantine can be a useful alternative to ketamine because the 
former is an NMDAr antagonist that has a pivotal action in the hippocampus of the brain. 
Glutamate activates the NMDAr, causing calcium (Ca2+) ions to move into the post-
synaptic neuron, triggering a signal cascade leading to long-term potentiation (LTP), 
producing a greater order of learning and memory [19]. NMDA can impair LTP in the 
hippocampus, but the action of memantine can prevent that effect [19]. This led to the 
theory that memantine could be used as a possible treatment for neuropathic pain due to 
an effect on the NMDA receptor, since the neurotransmitter glutamate is associated with 
neuropathic pain.  
Glutamate acting on an NMDA receptor causes the postsynaptic cell to become 
more sensitive to input signals. Memantine blocks excessive NMDA receptor activity 
without disturbing normal activity. The properties of memantine that allow such an effect 
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are that it is a noncompetitive, low-affinity, open-channel blocker. When the NMDA 
receptor-associated ion channel is excessively open, memantine acts as a fast-shut off but 
will not accumulate in the channel, allowing for normal synaptic transmission [20]. 
Memantine is highly absorbed after oral administration. Peak concentrations can 
be reached within 3-7 hours after administration and the intake of food does not affect the 
absorption of memantine. Memantine has a half-life of 60-80 hours and is mostly 
excreted by tubular secretion [4]. The majority of the administered memantine (57-82%) 
is excreted unchanged in the urine and the remaining percentage is converted primarily 
into three polar metabolites which possess minimal NMDA receptor antagonist activity 
[22].  
Minimal inhibition of CYP450 enzymes including CYP1A2, CYP2A6, CYP2C9, 
CYP2D6, CYP2E1, and CYP3A4 (most involved in biotransformation of opioids) have 
been observed in in vitro studies with memantine. Due to this low activity here, 
pharmacokinetic interactions with other medications metabolized by these enzymes are 
not likely [14]. 
An unpublished pilot investigational study on three geriatric patients taking a 
daily regimen of oxycodone/acetaminophen combinations for non-specific chronic pain 
for more than two months revealed that  adding  memantine orally for 28 days, following 
the approved FDA regimen for Alzheimer‘s Disease, allowed patients to reduce the 
amount of their pain medication [5] (Figure 1).  
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Figure 1. Effects of Namenda (memantine) on Oxycodone/acetaminophen 
Dosage over Four Weeks 
 
In a comprehensive randomized clinical trial, memantine was administered to 
improve post-operative pain from a breast cancer surgical treatment. This study was 
performed as a pilot clinical trial. Half of the patients received memantine both before 
and after surgery at an increasing dosage following the FDA approved schedule for 
Alzheimer‘s Disease (i.e., 5 mg a.m. on Week One, 5 mg a.m. and  p.m. on Week Two, 
10 mg a.m. and 5 mg p.m. on Week Three, 10 mg a.m. and 10 mg p.m. on Week 4), 
while the other group received a placebo (lactose) in the same time frame as the 
experimental group. At three months post-surgery, pain scores (0-10) were obtained and 
evaluated between control and memantine groups. Patients who received memantine 
reported less pain intensity, and less rescue analgesic (acetaminophen, NSAIDs, tramadol 
and morphine) dosage when matched with patients receiving only placebo. Pain scores 
were significantly lower in the memantine group (placebo: 1.3 ± 1.8; memantine: 0.2 ± 
0.4, p= 0.017). It was concluded that patients who underwent mastectomy had less 
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neuropathic pain and an improved state of well-being when memantine was added both 
before and after surgery compared to control [16].  
This correlates with an earlier study performed where six patients were treated 
with memantine for eight weeks after they had developed complex regional pain 
syndrome in the upper extremity following traumatic injury. In this investigation, 
memantine was given orally starting with 5 mg per day and increasing doses 5 mg every 
second day until a final target dose of 30 mg/d was achieved; it was also administered 
twice a day once the target dose was reached (15 mg/morning and 15 mg/evening). After 
six months post-treatment with memantine, all patients showed a significant decrease in 
pain scores dropping from an average score of 9.78 to 1.17 (p = 0.0001) [23].  
 In 2010, Gustin et al. performed a study in patients presenting with regional pain 
syndrome. They were given memantine as an adjunct to morphine to try to reduce their 
VAS pain score. Memantine was titrated from 5 to 40 mg over 15 days and maintained at 
40 mg for another 34 days in order to minimize side effects due to this combination 
therapy.  Patients who received memantine showed a significant difference in their VAS 
pain score at the affected limb by completing a numeric pain intensity scale (0—no pain, 
10—maximum pain) after active clenching of the hand (five times) and during rest (5.47 
to 1.40, p < 0.001). This indicates that using memantine as an adjunct to morphine 
improved analgesia. The mood of patients receiving memantine was also shown to 
significantly improve when compared to those who received a placebo (0.90 to 5.08, p < 
0.001). This was measured using the Center for Epidemiologic Studies Depression Scale, 
which is a numerical questionnaire and can be related to the reduction of pain [8].  
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A more recent similar study involved adding memantine to methadone as an 
adjunct. Patients were chosen according to the Diagnostic and Statistical Manual of 
Mental Disorders, fourth edition (DSM-IV) criteria for opioid-dependence. They were 
divided into randomized groups where one received a placebo plus methadone while the 
other group was administered memantine (5 mg memantine sustained-release capsule) for 
12 weeks with methadone. Results showed that the dosage of methadone required by 
patients also receiving memantine was significantly lower than the placebo group 
(p = 0.034); it decreased in  patients by 0.950 mg over the 12-week study period [12]. 
Results of these studies show that using memantine as an adjunct lowered the 
amount of pain, improved mood and decreased opioid dosage. 
  In this pilot study, memantine was added to patients taking immediate-release 
opioids, oxycodone, oxycodone/acetaminophen or hydromorphone, for at least two 
months; both office-based and nursing home patients were recruited. As a result of 
decreased opioid use, patients were hypothesized to experience fewer and/or less intense 
adverse effects; this outcome would be expected to improve their quality of life. 
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Chapter 2 
METHODS 
 
This pilot study was conducted to determine whether the addition of memantine to 
an established opioid analgesic regimen had measurable effects on analgesia, need for 
rescue pain medications or laxation. Objectives were to determine any reduction of daily 
dose of opioid medication, pain scores and constipation. This adjunctive agent was added 
to patients taking a combined oxycodone/acetaminophen formulation or hydromorphone 
for a minimum of two months. 
Approval to conduct this research was obtained from the Institutional Review 
Board (IRB) at Philadelphia College of Osteopathic Medicine (PCOM) for two nursing 
homes located in Philadelphia (Bala Nursing and Rehabilitation Center [B]; St. Ignatius 
Nursing Home [S]  on August 10, 2016. Additional IRB approval was obtained to recruit 
patients from the PCOM office-based practices of Katherine Galluzzi, DO, and Larry 
Finkelstein, DO on January 8, 2017. This study was an AB Design study, in which the 
patient initially did not receive treatment (A) and then was given the study drug (B).  
Inclusion criteria for this study were patients who are at least 18 years of age or older, 
taking opioids daily for two months for chronic pain, and able to sign the consent form. 
Patients were not able to participate in this study if they were taking certain 
antidepressants (TCAs and SNRIs) for less than 6 weeks, antipsychotics, or Alzheimer‘s 
Disease medication. Other exclusion criteria included non-English speaking patients or 
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those with, gastric motility problems, pregnancy, or planned pregnancy during the 6 
weeks of participation in this study. 
A screening process was performed by the attending physician and student 
investigators. Student investigators performed a Mini Mental State Exam (MMSE) 
(Appendix C) on patients that were reported to be on short-acting opioid therapy in order 
to gauge their cognitive function. The physician then contacted patients who were 
cognitively capable of participating to ask them to volunteer to be potential study 
subjects. After consulting with the potential study subject, the physician asked the patient 
to explain this study back to them in order to assure complete understanding of what was 
expected. Patients that were asked to volunteer for this study were then given a consent 
form (Appendix A) in which they could review with their families and significant others. 
After one week, patients were asked for their decision and if they had any questions that 
may have arisen; these were answered by their physician. To maintain confidentiality, 
signed consent form documents and pain diary documents were kept in a locked file 
cabinet, as required by the IRB. Patients who decided not to be part of the study or 
decided to stop in the middle of this investigation were assured that they would continue 
to receive the same care from the staff and their physician.  
Since this investigation was a pilot study with a small sample size and 
administration of memantine was off-label, it was not randomized, and a placebo was not 
used. Patients were allowed to use as much of their opioid daily as needed. Due to the 
fact that pain is variable from person to person, the amount of pain medication that each 
patient would require differs, therefore, each study subject served as his/her own control. 
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Memantine, provided from Verree Pharmacy located in Northeast Philadelphia, 
was given daily for 28 days in a row after a two-week pre-memantine phase to determine 
if the study patient could comply with all study requirements and to also obtain a baseline 
for the amount of opioid patients were taking, as well as their baseline pain score (Day 1- 
Day 14).  A baseline was important in order to identify existing patterns of the opioid use 
by the patient and allow for a more accurate interpretation of the results. Memantine was 
delivered in a kit prepared by Verree Pharmacy with five bottles in each to be 
administered to the patients by nursing staff at the nursing facility. Office out-patient 
memantine kits were delivered to PCOM and each weekly corresponding bottle was 
given to the patient each week when they came into the office. All bottles were labeled 
with the corresponding week, and a number, Week 3: Bottle 1: 7 tablets of 5 mg each, 
Week 4: Bottle 2: 14 tablets of 5mg each, Week 5: Bottle 3: 7 tablets of 5 mg each Week 
5: Bottle 4: 7 tablets of 10 mg each, Week 6: Bottle 5: 14 tablets of 10 mg each. Each 
bottle label also contained the date; subject ID, memantine dose per day, instructions, 
week number and physician name. Each was placed in a prescription bag with a unique 
kit number, with a label that included the number followed by Memantine-Opioid 
Clinical Investigation for research study use only.   
The first part of this study was the pre-memantine phase, in which memantine was 
not administered and patients were asked a series of questions in a weekly pain diary 
(Appendix B). The questions were, 1.) How much of your pain medicine you are taking 
every day? 2.) How much pain you are having every day? 3.) How many bowel 
movements you are having every day? Pain was assessed by using an 11 point scale, zero 
being no pain at all and 10 being the worst possible pain. During the two-week pre-
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memantine phase student investigators came in for a brief visit every day to learn how the 
patient was feeling. The patient then had a short discussion with their doctor regarding 
the desire to continue with this study. If the patient wanted to remain in the study, part 
two began immediately. During this phase, the patient took memantine for 28 days as 
follows, Week 3 – 5 mg in the morning for the first 7 days, Week 4 – 5 mg in the 
morning and 5 mg in the evening for the next 7 days, Week 5 – 10 mg in the morning and 
5 mg in the evening for the next 7 days, Week 6 –10 mg in the morning and 10 mg in the 
evening for the next 7 days (Appendix D). This titrated dosage regimen is exactly the 
dosage regimen approved by the FDA for treatment of Alzheimer‘s Disease. It was 
important to conduct a titration scale for this medication because patient comfort was of 
utmost importance. The risk of adverse effects from this medication is increased if not 
titrated properly. Administering memantine through this process to reach a target dose 
allowed physicians and nursing staff to monitor any adverse effects that may occur while 
taking the medication. Due to the fact that this was an off-label use of memantine, after 
the four week administration period, the patients did not receive continual administration 
of this medicine through this study. The cost of memantine for a four-week supply is 
$50.00 which was covered by the PCOM Center for Chronic Diseases of Aging for the 
duration of the investigation. If the patient wanted to continue to use memantine off-label 
after the study was completed, a prescription had to be written by the primary physician 
of the patient.  
For patients that resided in a nursing home, the first visit was a normal one where 
there was an initial identification of them for the study and discussion of the study; then 
the consent form was given. The next visit was for pre-study evaluation; if inclusion and 
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exclusion criteria were met, the patient was asked to sign the consent form, and Weeks 
one and two pain diary sheets were started. During the first week, student investigators 
visited the study subject in the afternoon and evening to ensure that the patient was 
compliant with the procedure (Day 1 –Day 7). The second week followed the schedule of 
the first week, in which the student investigators visited the patients to ensure they were 
remaining compliant with their daily pain diary logs (Day 8- Day 15). On Day 15, if the 
patient remained compliant, the treatment phase was started where memantine was 
administered and the pain diary sheets for Weeks three and four were started. Student 
investigators continued to meet with patients at the same time in the afternoon and 
evening (Day 16- Day 28). On Day 29 the treatment phase continued and diary sheets for 
Weeks five and six were started and student investigators continued to visit in the 
afternoon and evening (Day 29 – Day 42). Day 43 was the last visit and the end of 
participation for patients in this study. Student investigators visited the patient in the 
afternoon and evening to collect final data.  
The study subject was visited two times per day by student investigators, once at 
noon and once in the evening. There were a total of 84 visits over the six week study 
period and each visit took approximately three minutes, leading to a total of 4.2 hours of 
time spent with each study subject. At the nursing home, student investigators were 
granted access to their Millennium Database to gain access to patient records for data 
collection. Data was collected from the morning by the patient directly writing in the pain 
diary. Mid-day and evening data were collected via one-on-one interviews between 
patients and Student Investigators.  
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PCOM office out-patient data were collected on a weekly basis; however, the pain 
dairy information remained the same. The first visit was a normal visit where there was 
an initial identification for the study, discussion of the study and the consent form was 
given. The next visit, a week later, was the pre-study evaluation visit, where, if inclusion 
and exclusion criteria are met, the patient was asked to sign the consent form and week 
one pain diary was started. The patients came into the office each week of the study to 
hand in their pain diary for the previous week and start the pain diary for the next week. 
After the two week pre-memantine phase was completed to a satisfactory level, 
memantine was distributed to the patient in weekly bottles. The patient returned to the 
office each week to submit pain dairy data and to collect the next weekly dose of 
memantine until completion of the study. After the six-week study, all the data collected 
were combined. 
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Chapter 3 
 
RESULTS 
 
3.1. PART A 
 
 Patients who volunteered were given designated codes to de-identify them except 
to the investigators. Seven patients were involved, four from one of the nursing homes 
(B) and three office out-patients. Patients from the nursing home were designated as M 
[Male]-01-B, M-02-B, M-03-B and M-04-B. Office out-patients were designated as M-
01-R, M-02-R and F [Female]-01-R. However, three nursing home patients, M-02-B, M-
03-B and M-04-B, did not continue the study after the pre-memantine phase and did not 
receive any memantine.  
 Patients followed by this Student Investigator were M-01-B M-02-B, M-03-B, M-
04-B and F-01-R; those followed by Student Investigator, Lisa English, were M-01-R and 
M-02-R. 
 
3.1.1. Study Subject M-02-B 
He was an 81 year-old male with chronic hand and leg pain due to osteopenia. He 
received oxycodone, 5 mg + acetaminophen (oxy/acet) orally per os (p.o.), as needed pro 
re nata (prn), every six hours quaque sex hora (q6). This patient was removed from the 
study during the second week of the pre-memantine phase because he was not taking 
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enough of the generic combination of oxycodone, 5 mg + acetaminophen (oxy/acet) 
(Figure 2) and it would have been difficult to observe a reduction in his opioid intake 
throughout the study.  
 
Figure 2: Average Pain Scores and Bowel Movements per Week. Average weekly 
pain scores and bowel movements per day during the Pre-Memantine Phase of M-02-B. 
 
Once this patient was removed from the study, he started physical therapy and 
thought he would be using more oxy/acet.  Extensive monitoring was initiated to observe 
if he could be reintroduced into the study. Unfortunately, he passed away from a heart 
condition four days before starting memantine. 
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3.1.2. Study Subject M-03-B 
He was a 71 year-old male with chronic left side hip and leg pain due to an 
unspecified bone disorder and a fractured left femur. He received oxycodone 10 mg p.o. 
prn, every four hours quaque quarta hora (q4). This patient was able to complete the 
full-two week pre-memantine phase but when the memantine phase was to start, he was 
admitted to the hospital to undergo left hip surgery. Due to this unexpected event, the 
memantine phase was halted, and a decision was made remove the patient from the study. 
Another factor in his removal was a drop in pain scores from week one to week two 
(Figure 3). Due to this reduction without any intervention with memantine it would have 
been difficult to determine if the memantine, caused the decrease or it was due to a 
different cause. 
 
Figure 3: Pre-Memantine Phase; Daily opioid Dosage (mg). Daily opioid dosage (mg) 
for the length of time M-03-B was included in the study. 
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3.1.3. Study Subject M-04-B 
 
He was a 65 year old male with chronic back and leg pain who was taking 
oxy/acet 5-325 p.o. prn q6. This patient was taken out of the study after the first week of 
the Pre-Memantine Phase because he was not able to keep an accurate pain diary (Figure 
4). Also, he underwent surgery for a new pacemaker during the beginning of the second 
week of the Pre-Memantine Phase. Another factor in his elimination was his daily inquiry 
as to when he would be receiving the memantine even though the two week Pre-
Memantine Phase was explained to him every time. This was perceived as though the 
patient did not fully understand the study. 
 
Figure 4: Pre-Memantine Phase; Daily opioid Dosage (mg). Daily opioid dosage (mg) 
for the length of time M-04-B was included in the study. 
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office out-patients who would likely be more compliant, which would permit collection 
of more accurate data. 
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Chapter 4  
RESULTS 
 
4.1 PART B 
 
4.1.1. Study Subject M-01-B 
 
The first patient receiving memantine in this study, was a good candidate for this 
study because and was taking oxy/acet; this was administered via percutaneous 
endoscopic gastrostomy (PEG) tube, prn q4 for a pressure ulcer on his left heel, phantom 
pain from an amputated right fifth digit phalanx, and chest pain from the PEG tube. 
However, due to unforeseen circumstances, data accumulated from M-01-B are not as 
accurate as possible; however, they served as preliminary information to determine if a 
trend could be observed.  
The first circumstance was that the patient did not understand his oxy/acet 
prescription was prn and that he had to ask for it when needed. In the beginning, he 
assumed his opioid was given to him regularly. During the first week of the pre-
memantine phase he did not receive any for four days straight due to this 
misunderstanding (Figure 5). After explaining what ‗as needed‘ meant, the number of 
oxy/acet he received increased. Due to his confusion, it was decided to extend the pre-
memantine phase an additional week to obtain better data; the first week was renamed 
Week 0. This increased the study period from six to seven weeks in total.   
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4.1.1.1. Overview of Week Zero: 
 
Figure 5. Average Daily Pain Scores, Opioid Dosage (mg) and Bowel Movements per 
Day for Week Zero. Average daily pain scores, opioid dosage (mg) and bowel 
movements for each day of week zero. 
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There were times where oxy/acet given to the patient, but it was not recorded by the staff 
on their electronic medical records. On multiple occasions, the patient knew he had 
received oxy/acet even though it was not on the Medication Administration Record 
(MAR). When staff were questioned, it was confirmed that he was given oxy/acet but 
they failed to record the dosage in the MAR. Due to this circumstance the number of 
oxy/acet tablets the patient actually received may not be accurate; thus these data are 
likely skewed. The third circumstance happened when the patient used the emergency 
call button in his room to alert the staff that he needed an oxy/acet due to significant pain. 
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someone came to his room to give him an oxy/acet. It got to the point where the patient 
gave up trying to get the attention of the staff and just dealt with the pain. This further 
skews the data obtained from this patient because the actual amount of oxy/acet he 
needed was not reflected in the amount he was given. These issues were brought to the 
attention of the Director of Nursing which seemed to resolve the problems for a few days, 
but eventually they returned.  
There were also problems with the labels on the memantine bottles. Week 3 
should have been labeled 10 mg in the morning and 5 mg in the evening. However, 
unfortunately, the dosages were switched which resulted in the patient missing out on a 
10 mg dose on the first day of Week 3. Also for an unexplained reason, on the last day of 
Week 3, the memantine medication was discontinued which resulted in another missed 
10 mg dose on the first day of Week 4.  
Since there were many inconsistencies with this patient and his treatment plan, the 
data collected from him cannot be used in the final overall results for this study. 
However, they can be employed as preliminary results to observe if there were any 
changes.  
 
4.1.1.2. Pre-Memantine Phase 
 
Daily morning pain scores stayed fairly constant over the two week pre-
memantine phase (Figure 6).  
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4.1.1.2.1. Pain Scores 
 
 
Figure 6: Pre-memantine phase; Daily Morning Pain Scores . Daily morning pain 
scores over the two week pre-memantine phase. 
 
However, afternoon (Figure 7) and evening (Figure 8) reports dropped slightly 
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Figure 7: Pre-memantine phase; Daily Afternoon Pain Scores. Daily afternoon pain 
scores over the two week pre-memantine phase. 
 
 
Figure 8: Pre-memantine phase; Daily Evening Pain Scores . Daily evening pain 
scores over the two week pre-memantine phase. 
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 In the first two weeks there was a slight decrease in average daily pain scores 
from week one to week two (Figure 9). 
  
Figure 9: Pre-Memantine Phase; Average Daily Pain Scores . Averages of Morning, 
Afternoon and Evening pain scores for each day over the two week pre-memantine phase. 
 
 There was also a decrease in the average opioid dosage (mg) from week one to 
week two (Figure 10) and cannot be used to explain the decrease in average daily pain 
scores for this week.  
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4.1.1.2.2. Oxy/acet Dosage 
 
 
Figure 10: Pre-memantine phase; Daily Opioid Dosage (mg). Daily opioid dosages 
(mg) for each day over the two week pre-memantine phase. ? = discrepancies.  
 
There was also a slight decrease in bowel movements from week one to week two 
(Figure 11).  
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4.1.1.2.3 Bowel Movements 
 
 
Figure 11: Pre-memantine phase; Daily Bowel Movements.  Daily bowel movements 
for each day over the two week pre-memantine phase. 
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4.1.1.2.4. Overview of Pre-Memantine Phase 
 
 
Figure 12. Average Pain Scores, Opioid Dosage (mg) and Bowel Movements per 
Week. Average weekly pain scores, opioid dosage (mg) and bowel movements for the 
first two weeks of the study.  
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4.1.1.3. Week One of Memantine 
 
4.1.1.3.1. Pain Scores: 
 
 
Figure 13: Week One of Memantine (5 mg a.m.); Daily Pain Scores. Morning, 
afternoon and evening pain scores for each day over the first week of memantine. 
(*Patient spent 6+ hours in the hospital due to PEG tube needing to be replaced). 
 
Average daily pain scores for week one (Figure 14) remained fairly constant, as 
did opioid dosage (mg) (Figure 15).  
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Figure 14: Week One of Memantine; Average Daily Pain Scores. Averages of 
morning, afternoon and evening pain scores for each day over the first week of 
memantine. 
 
4.1.1.3.2. Oxy/acet Dosage 
 
Figure 15: Week One of Memantine; Daily Opioid Dosage (mg). Daily opioid dosages 
(mg) for each day of the first week of memantine. 
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Bowel movements for week one exhibited no remarkable characteristics (Figure 
16) but decreased slightly from the pre-memantine phase (Figure 17).  
 
4.1.1.3.3. Bowel Movements: 
 
 
Figure 16: Week One of Memantine; Daily Bowel Movements. Daily bowel 
movements for each day of the first week of memantine. 
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4.1.1.3.4. Overview through Week One of Memantine 
 
 
Figure 17. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly Pain Scores, Opioid Dosage (mg) and Bowel 
Movements for the first three weeks of the study. Arrow indicates when memantine was 
first introduced. 
 
4.1.1.4. Week Two of Memantine 
 
Week two of memantine (5 mg a.m.. & 5 mg p.m.) followed the same trend of 
week one of memantine with the afternoon pain scores being generally lower than the 
morning and evening pain scores (Figure 18).  
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4.1.1.4.1. Pain Scores 
 
 
Figure 18: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Pain Scores. 
Morning, afternoon and evening pain scores for each day over the second week of 
memantine.  
 
The average pain score during each day of Week Two of memantine did drop 
from the beginning to the end of the week (Figure 19).  
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Figure 19: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Average Daily Pain 
Scores. Averages of morning, afternoon and evening pain scores for each day over the 
second week of memantine. 
 
Daily opioid dosages (mg) for the second week of memantine were relatively 
constant with 5 or 10 mg throughout the week (Figure 20).  
  
 
 
 
 
 
 
 
 
 
6 
8 
6.3 6 6 
4.7 5 
0
1
2
3
4
5
6
7
8
9
A
ve
ra
ge
 D
ai
ly
 P
ai
n
 S
co
re
s 
Days of the Week 
Week  Two of Memantine (5 mg a.m. & 
5 mg p.m.); Average Daily Pain Scores 
38 
 
 
 
4.1.1.4.2. Oxy/acet Dosage 
 
 
Figure 20: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Opioid Dosage 
(mg). Daily opioid dosages (mg) for each day of the second week of memantine. ? = 
discrepancy.  
 
 Bowel movements for this week exhibited no unique characteristics (Figure 21) 
but increased slightly from the previous week (Figure 22).  
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4.1.1.4.3. Bowel Movements 
 
 
Figure 21: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Bowel 
Movements.  Daily bowel movements for each day of the second week of memantine. 
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4.1.1.4.4. Overview through Week Two of Memantine 
 
 
Figure 22. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, opioid dosage (mg) and bowel 
movements for the first four weeks of the study. arrow indicates when memantine was 
first introduced. 
 
4.1.1.5. Week Three of Memantine 
 
The trend followed into the third week of memantine (10 mg a.m. & 5 mg p.m.) 
(Figure 23).  
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4.1.1.5.1. Pain Scores 
 
 
Figure 23: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Pain Scores. 
Morning, afternoon and evening pain scores for each day over the third week of 
memantine. (*) = missed memantine dose.  
 
Afternoon pain scores were generally lower than both morning and evening pain 
scores but increased in the weekend. The average daily pain score for the third week 
stayed relatively constant, but were lower than that in week two (Figure 24).  
 
0
1
2
3
4
5
6
7
8
9
D
ai
ly
 P
ai
n
 S
co
re
s 
Days of the Week 
Week  Three of Memantine (10 mg a.m. & 5 
mg p.m.);  Daily Pain Scores 
Morning Afternoon Evening
* 
42 
 
 
 
 
Figure 24: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Average Daily 
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over 
the third week of memantine. 
 
Opioid dosage (mg) was also constant in week three; the patient received 10 mg 
in five of the seven days (Figure 25).  
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4.1.1.5.2. Oxy/acet Dosage 
 
 
Figure 25: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Opioid 
Dosage (mg). Daily opioid dosages (mg) for each day of week three. ? = discrepancies. 
 
Bowel movements for this week exhibited no unique characteristics (Figure 26) 
but decreased slightly from the previous week (Figure 27). 
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4.1.1.5.3. Bowel Movements 
 
Figure 26: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Bowel 
Movements.  Daily bowel movements for each day of week three. 
 
4.1.1.5.4. Overview through Week Three of Memantine 
   
Figure 27. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, opioid dosage (mg) and bowel 
movements for the first five weeks of the study. arrow indicates when memantine was 
first introduced. 
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4.1.1.6. Week Four of Memantine 
 
Data in the final week of memantine (10 mg a.m. & 10 mg p.m.) were constant 
with previous trends. Afternoon pain scores were generally lower than the morning and 
evening pain scores with an increase during the weekend (Figure 28).  
4.1.1.6.1. Pain Scores 
 
 
Figure 28: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Pain Scores. 
Morning, afternoon and evening pain scores for each day over the fourth week of 
memantine. (*) =  missed memantine dose. 
 
The average daily pain score for the fourth week stayed relatively constant again, 
but were lower than that in week three of memantine (Figure 29).  
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Figure 29: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Average Daily 
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over 
the fourth week of memantine. 
 
Opioid dosage (mg) was relatively consistent with the patient receiving either 5 or 
10 mg throughout each day (Figure 30).  
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4.1.1.6.2. Oxy/acet Dosage 
 
 
Figure 30: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Opioid 
Dosage (mg).  Daily opioid dosage (mg) for each day of week four. ? = discrepancy. 
 
Bowel movements increased during week four of memantine (Figure 31).  
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4.1.1.6.3. Bowel Movements 
 
 
Figure 31: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Bowel 
Movements.  Daily bowel movements for each day of week four. 
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4.1.1.6.4. Overview through Week Four of Memantine 
 
 
Figure 32. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, opioid dosage (mg) and bowel 
movements for each week of the study. Arrow indicates when memantine was first 
introduced. 
 
4.1.1.7. In-depth Overview of Study Subject M-01-B 
 
When compiling data from all six weeks of the study, trends were easier to 
observe. Average morning pain scores per week showed a decrease as the memantine 
dosage increased (Figure 33).  
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4.1.1.7.1. Pain Scores: 
 
 
Figure 33. Average Morning Pain Score Per Week. Average weekly morning pain 
scores for each week of the study. Arrow indicates when memantine was first introduced.  
 
The largest reduction in average pain score was in the afternoon (Figure 34). 
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Figure 34. Average Afternoon Pain Score Per Week. Average weekly afternoon pain 
scores for each week of the study. Arrow indicates when memantine was first introduced. 
 
 Average evening pain scores were similar to average morning reports, i.e. 
approximately the same values but still a noticeable decrease from the first week to the 
last (Figure 35).  
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Figure 35. Average Evening Pain Score Per Week. Average weekly evening pain 
scores for each week of the study. Arrow indicates when memantine was first introduced. 
 
The overall average pain scores per week decreased from week to week as the 
dosage of memantine increased (Figure 36).  
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Figure 36. Average Pain Score Per Week. Average weekly pain scores for each week 
of the study. Arrow indicates when memantine was first introduced. 
 
There was a 2.3 pain score decrease from week one to week six. Opioid dosage 
(mg) over the six weeks fluctuated slightly, however, there was a 3.5 mg decrease from 
week one to week six (Figure 37).  
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4.1.1.7.2. Oxy/acet Dosage 
 
 
Figure 37. Average Opioid Dosage (mg) per Day per Week. Average weekly opioid 
dosage (mg) per day for each week of the study. Arrow indicates when memantine was 
first introduced. 
 
The average bowel movements did not show an increase over the six weeks of the 
study (Figure 38). Week six average bowel movements were higher due to the one day 
where the patient recorded five bowel movements.  
  
 
 
 
 
 
8.6 
3.6 
7.1 
6.4 
7.1 
5.1 
0
2
4
6
8
10
12
1 2 3 4 5 6
A
ve
ag
e
 O
p
io
id
 (
m
g)
 
Week 
Average Opioid Dosage (mg) Per Week 
55 
 
 
 
4.1.1.7.3. Bowel Movements 
 
 
Figure 38. Bowel Movements per Week. Bowel movements for each week of the study. 
Arrow indicates when memantine was first introduced. 
 
 
4.1.2. Study Subject F-01-R: 
 
This patient was a good candidate for this study because she was taking 4 mg 
hydromorphone, prn, every eight hours quaque octava hora (q8) for joint pain from a 
motor vehicle accident decades ago; she was riding on her bike and was hit by a car. She 
presented with antalgic gait including pain when turning and the feeling of ―walking 
through molasses‖. This patient also experiences pain in the middle of the night, and 
stated that her joint pain appears to be weather-related. The weather that affects this 
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patient the most are rainy days and when the seasons are changing that brings along a 
barometric alteration. She also stated that she takes gabapentin 600 mg – 900 mg up to 
four times per day for restless leg, meclizine 50 mg per day for dizziness, Cymbalta 30 
mg per day for depression, Atorvastatin 20 mg per day to lower cholesterol, 
Hydrochlorothiazide (HCTZ) 25 mg per day to treat edema and metoprolol 50 mg per 
day to treat angina. 
 
4.1.2.1. Pre-Memantine Phase 
 
Over the two week pre-memantine phase, this patient experienced consistent pain 
scores in the morning, evening and afternoon. Her morning pain scores were all 5 or 6 
(Figure 39), afternoon pain scores were mostly 6 and 7, with only two pain scores of 8 
(Figure 40), and evening pain scores were all 8 with one night being a 9 (Figure 41).  
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4.1.2.1.1. Pain Scores: 
 
 
Figure 39: Pre-Memantine Phase; Daily Morning Pain Scores. Daily morning pain 
scores over the two week pre-memantine phase. 
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Figure 40: Pre-Memantine Phase; Daily Afternoon Pain Scores. Daily afternoon pain 
scores over the two week pre-memantine phase. 
 
  
Figure 41: Pre-Memantine Phase; Daily Evening Pain Scores. Daily evening pain 
scores over the two week pre-memantine phase. * = patient not able to rest all day. 
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The trend observed from the two week pre-memantine phase was that the patient 
recorded an increased pain score as the day proceeded with the highest pain scores in the 
evening (Figure 42). 
 
Figure 42: Pre-Memantine Phase; Daily Pain Scores. Daily morning, afternoon and 
evening pain scores over the two week pre-memantine phase. 
 
 However when comparing the average daily pain score for each day of the pre-
memantine phase, the average did not go lower than 6.3 or higher than a 7.3 (Figure 43).  
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Figure 43: Pre-Memantine Phase; Average Daily Pain Scores. Averages of Morning, 
Afternoon and Evening pain scores for each day over the two week pre-memantine phase. 
 
The amount of hydromorphone consumed by this patient remained consistent with 
12 mg total each day, except for one when the patient overslept and missed a 
hydromorphone dose in the morning (Figure 44).  
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4.1.2.1.2. Hydromorphone Dosage 
 
  
Figure 44: Pre-Memantine Phase; Daily Opioid Dosage (mg). Daily opioid dosages 
(mg) for each day over the two week pre-memantine phase. * = patient overslept and 
missed a usual dose.  
 
Bowel movements were unremarkable with only one bowel movement every 
couple of days (Figure 45).  
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4.1.2.1.3. Bowel Movements 
 
  
Figure 45: Pre-Memantine Phase; Daily Bowel Movements .  Daily bowel movements 
for each day over the two week pre-memantine phase.  
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4.1.2.1.4. Overview of Pre-Memantine Phase 
 
 
Figure 46. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and 
bowel movements for the first two weeks of the study. 
 
4.1.2.2. Week One of Memantine 
 
Daily pain scores for morning, afternoon and evening for the first week of 
memantine (5 mg a.m.) showed a trend of the morning and afternoon being 6 with a 
slight increase in the evening to pain scores of 7 and 8 (Figure 47).  
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4.1.2.2.1. Pain Scores 
 
 
Figure 47: Week One of Memantine (5 mg a.m.); Daily Pain Scores. Morning, 
afternoon and evening pain scores for each day over the first week of memantine. 
 
Compared to the pre-memantine phase data, she had on average a reduction in 
pain score at all times of the day. It also decreased (Figure 48) when compared to the pre-
memantine phase data.  
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Figure 48: Week One of Memantine (5 mg a.m.); Average Daily Pain Scores. 
Averages of morning, afternoon and evening pain scores for each day over the first week 
of memantine. 
 
For week one of memantine the average daily pain score was either 6.3 or 6.7, 
whereas during the pre-memantine phase, there were a few days that reached a pain score 
of 7.3. However, daily opioid dosage (mg) remained constant at 12 mg (Figure 49). 
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4.1.2.2.2. Hydromorphone Dosage 
 
 
Figure 49: Week One of Memantine (5 mg a.m.); Daily Opioid Dosage (mg). Daily 
opioid dosages (mg) for each day of the first week of memantine. 
 
 Daily bowel movements did decrease slightly (Figure 50) from three bowel 
movements per week during the pre-memantine phase to two for the first week of 
memantine.  
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4.1.2.2.3. Bowel Movements 
 
 
Figure 50: Week One of Memantine (5 mg a.m.); Daily Bowel Movements.  Daily 
bowel movements for each day of the first week of memantine. 
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4.1.2.2.4. Overview through Week One of Memantine 
 
 
Figure 51. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and 
bowel movements for the first three weeks of the study. Arrow indicates when 
memantine was first introduced. 
 
4.1.2.3. Week Two of Memantine 
 
In daily pain scores for morning, afternoon and evening for the second week of 
memantine (5 mg a.m. & 5 mg p.m.) there was a trend of the first two with a score of 6; 
there were two instances where a pain score of 8 was recorded in the afternoon. Evening 
pain scores were almost all 7 (Figure 52).  
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4.1.2.3.1.Pain Scores 
 
 
Figure 52: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Pain Scores. 
Morning, Afternoon and evening pain scores for each day over the second week of 
memantine. Increased afternoon pain scores due to weather-related neck pain.  
 
When observing the average daily pain score over each day of week two of 
memantine and comparing it to data from week one, there were more  averages of 6.3, 
however, one day it was a 7.0 (Figure 53). 
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Figure 53: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Average Daily Pain 
Scores. Averages of morning, afternoon and evening pain scores for each day over the 
second week of memantine. 
 
 Daily opioid dosages (mg) for the second week of memantine dropped due to the 
patient taking one less hydromorphone on Thursday, Friday and Saturday (Figure 54).  
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4.1.2.3.2. Hydromorphone Dosage 
 
 
Figure 54: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Opioid Dosage 
(mg). Daily opioid dosages (mg) for each day of the second week of memantine.  
 
Bowel movements for this week showed no special characteristics (Figure 55) but 
decreased by a factor of 0.1 when compared to the pre-memantine phase (Figure 56).  
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4.1.2.3.3. Bowel Movements 
 
 
Figure 55: Week Two of Memantine (5 mg a.m. & 5 mg p.m.); Daily Bowel 
Movements.  Daily bowel movements for each day of the second week of memantine. 
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4.1.2.3.4. Overview through Week Two of Memantine 
 
 
Figure 56. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and 
bowel movements for the first four weeks of the study. Arrow indicates when memantine 
was first introduced. 
 
4.1.2.4. Week Three of Memantine 
 
When looking at daily pain scores for morning, afternoon and evening for the 
third week of memantine (10 mg a.m. & 5 mg p.m.) there was a decreasing trend with 
mid-week stabilization (Figure 57). 
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4.1.2.4.1. Pain Scores 
 
 
Figure 57: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Pain Scores. 
Morning, afternoon and evening pain scores for each day over the third week of 
memantine. 
 
Monday was the worst day with a pain score of 9 recorded all day. From Tuesday 
through Saturday the patient had an average daily pain score of 6, with a decrease to a 
pain score of 5 on Sunday (Figure 58).  
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Figure 58: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Average Daily 
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over 
the third week of memantine. Patient describes the highest pain score is due to weather. 
 
This decrease in pain score was accompanied by a reduction in hydromorphone 
i.e., 4 mg less each day (Figure 59).  
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4.1.2.4.2. Hydromorphone Dosage 
 
 
Figure 59: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Opioid 
Dosage (mg). Daily opioid dosages (mg) for each day of the third week of memantine. 
 
Bowel movements stayed consistent with only two bowel movements this week 
(Figure 60), although the average bowel movements per day per week have only 
decreased by a factor of 0.1 (Figure 61). 
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4.1.2.4.3. Bowel Movements 
 
 
Figure 60: Week Three of Memantine (10 mg a.m. & 5 mg p.m.); Daily Bowel 
Movements.  Daily bowel movements for each day of week three. 
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4.1.2.4.4. Overview through Week Three of Memantine 
 
  
Figure 61. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and 
bowel movements for the first five weeks of the study. Arrow indicates when memantine 
was first introduced. 
 
4.1.2.5. Week Four of Memantine: 
 
In the final week, of memantine (10 mg a.m. & 10 mg p.m.) there was an 
improvement in morning pain scores, i.e., recorded pain scores were 5 for each day; 
afternoon and evening pain scores stayed relatively consistent from the previous week 
(Figure 62).  
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4.1.2.5.1. Pain Scores 
 
 
Figure 62: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Pain Scores. 
Morning, afternoon and evening pain scores for each day over the fourth week of 
memantine. 
 
The average daily pain score for the fourth week were relatively the lowest of the 
whole study, i.e., five out of seven days the patient had an average pain score of only 5.7 
(Figure 63).  
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Figure 63: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Average Daily 
Pain Scores. Averages of morning, afternoon and evening pain scores for each day over 
the fourth week of memantine. 
 
Opioid dosage (mg) decreased further in that the patient needed to take only two 4 
mg hydromorphone every day except for Easter Sunday due to lack of rest time (Figure 
64).  
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4.1.2.5.2. Hydromorphone Dosage 
 
 
Figure 64: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Opioid 
Dosage (mg).  Daily opioid dosage for each day of week four. 
 
Even with a decreased hydromorphone dose, pain scores continued to decrease. 
Bowel movements stayed consistent during week four of memantine (Figure 65).  
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4.1.2.5.3. Bowel Movements 
 
 
Figure 65: Week Four of Memantine (10 mg a.m. & 10 mg p.m.); Daily Bowel 
Movements.  Daily bowel movements for each day of week four. 
 
She stated that the only side effect was constipation, but bowel movements 
decreased by a factor of only 0.1 per day per week. (Figure 66).  
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4.1.2.5.4. Overview through Week Four of Memantine 
 
 
Figure 66. Average Pain Scores, Average Opioid Dosage (mg) and Bowel 
Movements per Week. Average weekly pain scores, average opioid dosage (mg) and 
bowel movements for each week of the study. Arrow indicates when memantine was first 
introduced. 
 
4.1.2.6. In-depth Overview of Study Subject F-01-R: 
 
When compiling all data from the six weeks of the study trends are easier to 
observe. The average morning pain scores per week actually increased as the memantine 
dosage increased except for the last week when it was the lowest of the entire study 
(Figure 67). 
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4.1.2.6.1. Pain Scores 
 
Figure 67. Average Morning Pain Score Per Week. Average weekly morning pain 
scores for each week of the study. Arrow indicates when memantine was first introduced.  
 
 Average afternoon pain scores decreased as memantine dosage was increased; 
they moved from an average of 6.9 during the pre-memantine phase to 6.1 (Figure 68).  
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Figure 68. Average Afternoon Pain Score Per Week. Average weekly afternoon pain 
scores for each week of the study. Arrow indicates when memantine was first introduced. 
The largest reduction in pain score was the average evening result; it decreased 
from 8.1 to 6.6 (Figure 69).  
 
Figure 69. Average Evening Pain Score Per Week. Average weekly evening pain 
scores for each week of the study. Arrow indicates when memantine was first introduced. 
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Overall average pain scores per week decreased from week to week as memantine 
dosage was raised (Figure 70). 
 
Figure 70. Average Pain Score Per Week. Average weekly pain scores for each week 
of the study. Arrow indicates when memantine was first introduced. 
 
 The patient was at an average pain score of 6.9 during the pre-memantine phase 
but dropped to 5.9 after the fourth week of memantine. Although this is only a decrease 
in pain score by a factor of 1, the patient was taking less of her opioid. Opioid dosage 
(mg) over the six weeks decreased from an average of 12 mg to an average of 8.6 mg 
(Figure 71).  
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4.1.2.6.2. Hydromorphone Dosage 
 
 
Figure 71. Average Opioid Dosage (mg) per Day per Week. Average weekly opioid 
dosage (mg) per day for each week of the study. Arrow indicates when memantine was 
first introduced. 
 
The number of bowel movements did not show an increase over the six weeks of 
the study (Figure 72).  
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4.1.2.6.3. Bowel Movements 
 
 
Figure 72. Bowel Movements per Week. Average bowel movements per day for each 
week of the study. Arrow indicates when memantine was first introduced. 
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Chapter 5 
 
DISCUSSION 
 
  This pilot study demonstrated trends of positive effectivness of memantine 
although there were only a limited number of patients. While pateints can have different 
etiologies of pain, opioids work by targeting the μ-receptor, a sub-class of opioid receptor 
that is anti-nociceptive, thus making patients taking this medication comparable. The type 
of opioid medication used by each patient was different, however, the similarities 
between oxy/acet and hydromorphone made them suitable medications for this study. 
They mainly work on the μ1 and μ2 receptors. The former, when activated, is responsible 
for supraspinal analgesia whereas activation of the latter produces spinal analgesia, 
respiratory depression and constipation [10].  Memantine reduces glutamate activity at 
the NMDA receptor, and therefore has been shown to reduce pain. One mechanism of 
pain transmission involves glutamate activating the NMDA receptor, causing an influx of 
calcium ions into the post-synaptic neuron, making it more sensitive and more easily 
depolarized; adding memantine reduces calcium flow from excess glutamate, reducing 
the pain signal.  
Oxycodone and hydromorphone are prescription opioids. Oxycodone is the main 
ingredient in Percocet® along with acetaminophen; brand names for hydromorphone are 
Dilaudid® and Exalgo®. Oxycodone and hydromorphone have similar properties; both 
can be administered in tablet form or available as a liquid. They are ideal for patients that 
have been taking opioids for an extended period of time and can benefit from a higher, 
controlled dose due to the fact that both are also available in extended-release forms. 
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However hydromorphone is stronger than oxycodone and are often prescribed for more 
severe pain that stems from surgery, broken bones, and cancer [21].  
Dosage requirements for these drugs depend on a few factors. Elements that 
control the dosages are whether the drugs are in tablet form or liquid form, due to the 
liquid form having a faster absorption rate, type of pain, source of pain, and if the patient 
is in need of immediate-release or extended-release. If tolerance develops, both 
oxycodone and hydromorphone strength can be increased.  Since cross-tolerance is 
incomplete among opioids, a common practice for physicians is to switch the type of 
opioid the patient is taking to extended-release if they have been on that drug for a long 
time with increasing dosages [21]. 
Side effects for each drug are similar due to similar shared properties. However, 
since hydromorphone is a more potent drug, side effects experienced when taking this 
drug can be more severe. The most common severe side effects for both of these drugs 
are shallow or light breathing, constipation (more severe with extended-release 
hydromorphone), drowsiness, dizziness and nausea. Less common severe side effects 
include respiratory depression, seizures, hallucinations and ataxia. Side effects that are 
relatively exclusive to hydromorphone when compared to oxycodone are heart 
palpitations, respiratory complications and skin rashes. It is recommended to avoid 
driving while taking these drugs due to the fact that both reduce judgment and physical 
skills. Withdrawal symptoms are also very likely if one was to suddenly stop taking the 
medication after a long-term use; they include gastrointestinal complications, cramping, 
nausea, depression and agitation. It is recommended to taper off the medication slowly. 
On the other end of the spectrum, both drugs can lead to overdose if too much is taken. A 
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child can have a fatal overdose on just one extended-release hydromorphone tablet due to 
high potency [21]. 
Hydromorphone has a black box warning on the label. This means that research 
has proven it can have serious and even life-threatening side effects. Respiratory 
depression causes the most concern. In addition, hydromorphone can cause hypotension. 
Oxycodone and hydromorphone can enhance the depressant effects of alcohol; both can 
also cause gastrointestinal complications such as nausea, vomiting, constipation, loss of 
appetite. 
 Potential side effects of memantine (Namenda®) with an incidence greater than 
5% are confusion (6%), dizziness (7%) and headache (6%) [4]. In placebo-controlled 
trials in which dementia patients received doses of memantine up to 20 mg/day, the 
likelihood of discontinuation because of an adverse event was the same in the memantine 
group as in the placebo group, i.e. <1% [4]. 
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Table 1: Adverse Events Reported in Controlled Clinical 
Trials in at Least 2% of Patients Receiving Namenda and 
at a Higher Frequency than Placebo-treated Patients. [4] 
Body System 
     Adverse Event 
Placebo 
(N = 922) 
% 
Namenda 
(N = 940) 
% 
Body as a Whole   
     Fatigue 1 2 
     Pain 1 3 
Cardiovascular System   
     Hypertension 2 4 
Central and Peripheral 
Nervous System 
  
     Dizziness 5 7 
     Headache 3 6 
Gastrointestinal System   
     Constipation 3 5 
     Vomiting 2 3 
Musculoskeletal System   
     Back pain 2 3 
Psychiatric Disorders   
     Confusion 5 6 
     Somnolence 2 3 
     Hallucination 2 3 
Respiratory System   
     Coughing 3 4 
     Dyspnea 1 2 
 
 
5.1. Study Patient M-01-B 
The first nursing home patient to complete this study was a 79 year-old male, 
taking oxy/acet for a pressure ulcer, phantom pain and PEG-tube discomfort. There were 
some small reductions in all measurements without the addition of memantine; this may 
have been to an expectation (mindset) that analgesia was going to occur as a result of 
being in the study [3]. Therefore, it was difficult to determine how much it contributed to 
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reducing parameters of this patient. However, some trends were observed over the 
remaining four weeks when memantine was administered.  
Evaluation of daily morning, afternoon and evening pain scores for the first week 
of memantine (5 mg a.m.), showed that the former was lower after taking 5 mg of 
memantine in the morning. There was an anomaly; it occurred on the Friday of the first 
week of memantine (*) (Figure 13). The patient was taken to the hospital Thursday night 
because his PEG tube came out and it had to be replaced immediately. Due to the pain in 
his feet, it is hard for this patient to walk and he relies on a wheel chair to get around. He 
spent over six hours waiting in the hospital to be treated. The tape that the physicians 
used pulled his skin causing a rash and increased irritation and pain. The patient did not 
take an oxy/acet at the hospital because he did not want to stay there over-night; he just 
endured the pain. This likely caused pain scores to become higher on Friday when he 
returned to the nursing home. 
Two noticeable differences were Saturday and Sunday of the third week of 
memantine, where pain scores were slightly elevated (Figure 23). This may have been 
due to the fact that weekend nurses are different than those on staff during the week; the 
former group may not know the patient as well. Since this group is changing weekend by 
weekend, they have less experience with the patient and did not recognize his situation at 
a deeper, meaningful clinical level.  This may have led to the patient to not get his 
medication as quickly, resulting in increased pain. 
Bowel movements increased during the final week of memantine. This may be 
attributed to the fact that his diet mainly consists of pureed food due to his PEG tube and 
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on Friday of that week he ate a piece of meatloaf by mouth that he received from another 
patient; his gastrointestinal tract may have not been able to handle it (Figure 32).  
This patient decided not to continue memantine medication after the study was 
completed, due to the fact that he did not notice a difference in his way of life. However, 
with data collected from this patient, it was evident that his pain score decreased 
dramatically over the six-week study. Opioid dosage also decreased but may be attributed 
to anomalies that occurred during the study. Bowel movements fluctuated and did not 
show a certain trend. 
 
5.2. Study Patient F-01-R 
 
 The second patient that completed this study was a female office-out patient who 
is 69 years old, taking hydromorphone for joint pain and altered gait.  
The Sunday of the second week of the pre-memantine phase there was increase in 
pain score likely due to the patient not being able to rest because she was busy with 
friends and family (Figure 42). There was an increase in opioid dosage from week one of 
the pre-memantine phase to the second week due to a missed dose in the first week. 
However, instead of doubling up the dosage later, or taking the missed dosage too close 
to the second dose, the patient decided to refrain from taking the first one, resulting in a 
lower average for the first week (Figure 44). 
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This patient described significant improvement during this first week of 
memantine and stated that she ―felt great‖. She now wanted to participate in activities 
more of the time instead of always wanting to lay down to rest. F-01-R stated her pain 
was less in the evening (Figure 47), with less fatigue, more clear-headedness, more 
strength in her lower extremity, being able to sit up and stand faster after being seated for 
a while, less hip pain, and having a more positive attitude. She also recorded taking 25 
mg less meclizine during this week (prescribed for her dizziness) and stated that no other 
drug has made her feel this great after taking it.  
Sunday of the second week of memantine was another busy day for the patient 
where she was unable to rest as much as usual. This likely caused her pain scores to be 
slightly increased for that day (Figure 52). The patient started to decrease the amount of 
opioid she was taking this week and was able to take one 4 mg hydromorphone less on 
Thursday, Friday and Saturday (Figure 54). Although, there was not a decrease in 
average pain score, the patient experienced no increase in pain when taking less opioid 
along with memantine. At the end of the second week she described some dizziness and 
nausea, but attributed those symptoms to the re-occurring neck pain, concluding that they 
are nothing new and thus unrelated to memantine. This patient also noted that she still felt 
as if memantine was giving her a clearer head and the ability to feel pain differently such 
that she was able to isolate the exact location of the pain, instead of her whole body being 
in pain. 
F-01-R described the third week of memantine as her best at that point in the 
study, and was amazed at how well she was feeling. All doses of gabapentin, meclizine 
and hydromorphone had decreased. Gabapentin was reduced from 600 mg, four times a 
96 
 
 
 
day to 300 mg three times per day, meclizine from 50 mg to 25 mg, and hydromorphone 
from 12 mg per day to 8 mg per day. Monday was the worst day with a pain score of 9 
recorded at each point (Figure 58). The patient attributed this to the weather and the fused 
vertebrae in her neck. However, after taking the first 10 mg dose of memantine and 
waking up the next day, the patient felt like she had a ―make-over‖, every part of her 
body felt great. There was a decrease in pain score throughout the week, along with a 
decrease in hydromorphone dose (Figure 59). However, even with a decrease in 
hydromorphone, the patient described an increase in constipation which indicates that she 
may be part of the 5% of patients that experience constipation while using memantine. 
However, her bowel movements stayed constant at two per week during memantine 
treatment which is only one lower than the pre-memantine phase baseline of three bowel 
movements per week (Figure 61). This patient also reported no nausea or dizziness this 
week and felt as though she wanted to get more involved in daily activities due to her 
increase in well-being. Normally, F-01-R goes to bed early due to being in pain from the 
day, but this week she stayed out at a concert until 10 o‘clock p.m. and was still alert. She 
even felt well enough to wake up early and make it to morning Mass, whereas she would 
usually wait to go to evening Mass. 
Sunday of the fourth week of memantine there was an increase in pain score 
likely due to it being a holiday event and the patient was not able to rest as much as usual 
(Figure 62). 
Pain score decreased slightly but was accompanied by a larger decrease in opioid 
dosage. This showed that memantine had a definitive effect on the pain the patient was 
experiencing. She also decided to continue with memantine after the study due to how 
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well this medication made her feel. A follow-up on this patient revealed that she is 
continuing to take only 8 mg of hydromorphone a day and her level of pain has stabilized 
to slightly lower than before the study. She claims memantine is ―working better and 
better each day”.  
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Chapter 6 
CONCLUSIONS 
Adding memantine as an adjunct to daily opioid use in a chronic non-malignant 
pain condition reduced overall pain scores in two patients, whereas a decrease in opioid 
dosage and a slight reduction in bowel movements occurred only in one. It was the 
intention to observe differences between males and females but since only one of each 
gender was studied in the time-frame allotted for this study and the opioids were 
different, it was not possible to evaluate any distinction.  However, this pilot study 
allowed insight to using memantine as an adjunct to treat chronic non-malignant pain 
patients who take an opioid daily.  
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Chapter 7 
FUTURE DIRECTIONS 
 With the number of setbacks occurring at the beginning of this study, going 
forward some aspects will need to be changed. Future work will require a more in-depth 
review of the nursing homes to ensure that they have an adequate number of qualified 
staff to handle patients that are involved in a clinical study, allowing for more accurate 
data to be collected. In order to obtain a larger sample size, researchers could expand the 
type of opioid medication the patients are using, instead of limiting the study to only two 
types of opioids and expanding the amount of nursing home facilities or number of 
medical offices with out-patients. This may increase the prospective patient size and 
more patients may then be able to be recruited. With a larger patient sample size, 
comparing how memantine could affect both males and females may become possible.  
  Other data that would be interesting to obtain from this study in the future would 
be to try to observe if there is a certain amount of opioid dosage reduction in which it 
would increase gastric motility, and also to try to observe any differences over a larger 
age range. One thing to ask future test subjects would be to record any over-the-counter 
medications they are using and identify if they cause additional gastrointestinal problems. 
Researchers could then report if the complications from those medications are low or not 
a factor.  
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APPENDIX B: PAIN DIARY WEEK 1 (FRONT) 
RESEARCH STUDY TO REDUCE OPIOID PAIN 
 MEDICATION USE IN PATIENTS BY ADDING MEMANTINE 
 
PAIN AND MEDICATION DIARY- WEEK ONE 
 
If you have any questions or concerns about this research, 
please call Dr___________________    at 
______________. 
 
Before you turn to the next page, please answer these 
questions: 
 
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE 
PAIN?      ___NO   ___YES.     IF ‗YES‘ PLEASE WRITE DOWN WHAT 
HAPPENED. 
 
 
 
 
 
 
 
 
 
DID  YOU  HAVE  BAD  EFFECTS  FROM  THE  DRUGS  DURING  THIS  
WEEK? 
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE. 
 
 
 
 
APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
Patient Name (Please Print) _____________________________________________ 
 
Telephone:    Home: ____________________     Work ________________________ 
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APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
 
                                                 PAIN  SCORE 
 
              ___________________________________________________ 
              0       1       2        3        4        5        6        7        8        9       10 
   I HAVE                                                                                                    THIS IS THE  
NO PAIN                                                                                                    WORST PAIN 
                                                                                                                   I EVER HAD 
 
 
DATE COMPLETED ___________________________     
 
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.  
 
 
Thank you for joining our important study. 
 
 
 
 
 
Week 1 
How many 
oxycodone or 
oxycodone / 
acetaminophen 
tablets did you 
take today? 
 
 
What was 
your pain 
score this 
morning? 
 
 
What was 
your pain 
score this 
afternoon? 
 
 
What was 
your pain 
score 
tonight? 
 
How many 
bowel 
movements 
did you have 
today? 
Day 1: 
 
 
     
      
Day 2: 
 
 
     
      
Day 3: 
 
 
     
      
Day 4: 
 
 
     
      
Day 5: 
 
 
     
      
Day 6: 
 
 
     
      
Day 7: 
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APPENDIX B: PAIN DIARY WEEK 2 (FRONT) 
RESEARCH STUDY TO REDUCE OPIOID PAIN 
 MEDICATION USE IN PATIENTS BY ADDING MEMANTINE 
 
PAIN AND MEDICATION DIARY- WEEK TWO 
 
If you have any questions or concerns about this research, 
please call Dr___________________    at 
______________. 
 
Before you turn to the next page, please answer these 
questions: 
 
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE 
PAIN?      ___NO   ___YES.     IF ‗YES‘ PLEASE WRITE DOWN WHAT 
HAPPENED. 
 
 
 
 
 
 
 
 
 
DID  YOU  HAVE  BAD  EFFECTS  FROM  THE  DRUGS  DURING  THIS  
WEEK? 
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE. 
 
 
 
 
APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
Patient Name (Please Print) _____________________________________________ 
 
 
 
 
 
 
 
 
 
 
 
110 
 
 
 
APPENDIX B: PAIN DIARY WEEK 2 (BACK) 
 
 
                                                 PAIN  SCORE 
 
              ___________________________________________________ 
              0       1       2        3        4        5        6        7        8        9       10 
   I HAVE                                                                                                    THIS IS THE  
NO PAIN                                                                                                    WORST PAIN 
                                                                                                                   I EVER HAD 
 
 
DATE COMPLETED ___________________________     
 
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.  
 
 
Thank you for joining our important study. 
 
 
 
 
 
Week 2 
How many 
oxycodone or 
oxycodone / 
acetaminophen 
tablets did you 
take today? 
 
 
What was 
your pain 
score this 
morning? 
 
 
What was 
your pain 
score this 
afternoon? 
 
 
What was 
your pain 
score 
tonight? 
 
How many 
bowel 
movements 
did you have 
today? 
Day 1: 
 
 
     
      
Day 2: 
 
 
     
      
Day 3: 
 
 
     
      
Day 4: 
 
 
     
      
Day 5: 
 
 
     
      
Day 6: 
 
 
     
      
Day 7: 
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APPENDIX B: PAIN DIARY WEEK 3 (FRONT) 
RESEARCH STUDY TO REDUCE OPIOID PAIN 
 MEDICATION USE IN PATIENTS BY ADDING MEMANTINE 
 
PAIN AND MEDICATION DIARY- WEEK THREE 
 
If you have any questions or concerns about this research, 
please call Dr___________________    at 
______________. 
 
Before you turn to the next page, please answer these 
questions: 
 
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE 
PAIN?      ___NO   ___YES.     IF ‗YES‘ PLEASE WRITE DOWN WHAT 
HAPPENED. 
 
 
 
 
 
 
 
 
 
DID  YOU  HAVE  BAD  EFFECTS  FROM  THE  DRUGS  DURING  THIS  
WEEK? 
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE. 
 
 
 
 
APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
Patient Name (Please Print) _____________________________________________ 
 
Telephone:    Home: ____________________     Work ________________________ 
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APPENDIX B: PAIN DIARY WEEK 3 (BACK) 
 
 
                                                 PAIN  SCORE 
 
              ___________________________________________________ 
              0       1       2        3        4        5        6        7        8        9       10 
   I HAVE                                                                                                    THIS IS THE  
NO PAIN                                                                                                    WORST PAIN 
                                                                                                                   I EVER HAD 
 
 
DATE COMPLETED ___________________________     
 
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.  
 
 
Thank you for joining our important study. 
 
 
 
 
 
Week 3 
How many 
oxycodone or 
oxycodone / 
acetaminophen 
tablets did you 
take today? 
 
 
What was 
your pain 
score this 
morning? 
 
 
What was 
your pain 
score this 
afternoon? 
 
 
What was 
your pain 
score 
tonight? 
 
How many 
bowel 
movements 
did you have 
today? 
Day 1: 
 
 
     
      
Day 2: 
 
 
     
      
Day 3: 
 
 
     
      
Day 4: 
 
 
     
      
Day 5: 
 
 
     
      
Day 6: 
 
 
     
      
Day 7: 
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APPENDIX B: PAIN DIARY WEEK 4 (FRONT) 
RESEARCH STUDY TO REDUCE OPIOID PAIN 
 MEDICATION USE IN PATIENTS BY ADDING MEMANTINE 
 
PAIN AND MEDICATION DIARY- WEEK FOUR 
 
If you have any questions or concerns about this research, 
please call Dr___________________    at 
______________. 
 
Before you turn to the next page, please answer these 
questions: 
 
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE 
PAIN?      ___NO   ___YES.     IF ‗YES‘ PLEASE WRITE DOWN WHAT 
HAPPENED. 
 
 
 
 
 
 
 
 
 
DID  YOU  HAVE  BAD  EFFECTS  FROM  THE  DRUGS  DURING  THIS  
WEEK? 
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE. 
 
 
 
 
APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
Patient Name (Please Print) _____________________________________________ 
 
Telephone:    Home: ____________________     Work ________________________ 
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APPENDIX B: PAIN DIARY WEEK 4 (BACK) 
 
 
                                                 PAIN  SCORE 
 
              ___________________________________________________ 
              0       1       2        3        4        5        6        7        8        9       10 
   I HAVE                                                                                                    THIS IS THE  
NO PAIN                                                                                                    WORST PAIN 
                                                                                                                   I EVER HAD 
 
 
DATE COMPLETED ___________________________     
 
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.  
 
 
Thank you for joining our important study. 
 
 
 
 
 
Week 4 
How many 
oxycodone or 
oxycodone / 
acetaminophen 
tablets did you 
take today? 
 
 
What was 
your pain 
score this 
morning? 
 
 
What was 
your pain 
score this 
afternoon? 
 
 
What was 
your pain 
score 
tonight? 
 
How many 
bowel 
movements 
did you have 
today? 
Day 1: 
 
 
     
      
Day 2: 
 
 
     
      
Day 3: 
 
 
     
      
Day 4: 
 
 
     
      
Day 5: 
 
 
     
      
Day 6: 
 
 
     
      
Day 7: 
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APPENDIX B: PAIN DIARY WEEK 5 (FRONT) 
RESEARCH STUDY TO REDUCE OPIOID PAIN 
 MEDICATION USE IN PATIENTS BY ADDING MEMANTINE 
 
PAIN AND MEDICATION DIARY- WEEK FIVE 
 
If you have any questions or concerns about this research, 
please call Dr___________________    at 
______________. 
 
Before you turn to the next page, please answer these 
questions: 
 
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE 
PAIN?      ___NO   ___YES.     IF ‗YES‘ PLEASE WRITE DOWN WHAT 
HAPPENED. 
 
 
 
 
 
 
 
 
 
DID  YOU  HAVE  BAD  EFFECTS  FROM  THE  DRUGS  DURING  THIS  
WEEK? 
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE. 
 
 
 
 
APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
Patient Name (Please Print) _____________________________________________ 
 
Telephone:    Home: ____________________     Work ________________________ 
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APPENDIX B: PAIN DIARY WEEK 5 (BACK) 
 
 
                                                 PAIN  SCORE 
 
              ___________________________________________________ 
              0       1       2        3        4        5        6        7        8        9       10 
   I HAVE                                                                                                    THIS IS THE  
NO PAIN                                                                                                    WORST PAIN 
                                                                                                                   I EVER HAD 
 
 
DATE COMPLETED ___________________________     
 
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.  
 
 
Thank you for joining our important study. 
 
 
 
 
 
Week 5 
How many 
oxycodone or 
oxycodone / 
acetaminophen 
tablets did you 
take today? 
 
 
What was 
your pain 
score this 
morning? 
 
 
What was 
your pain 
score this 
afternoon? 
 
 
What was 
your pain 
score 
tonight? 
 
How many 
bowel 
movements 
did you have 
today? 
Day 1: 
 
 
     
      
Day 2: 
 
 
     
      
Day 3: 
 
 
     
      
Day 4: 
 
 
     
      
Day 5: 
 
 
     
      
Day 6: 
 
 
     
      
Day 7: 
 
 
     
117 
 
 
 
APPENDIX B: PAIN DIARY WEEK 6 (FRONT) 
RESEARCH STUDY TO REDUCE OPIOID PAIN 
 MEDICATION USE IN PATIENTS BY ADDING MEMANTINE 
 
PAIN AND MEDICATION DIARY- WEEK SIX 
 
If you have any questions or concerns about this research, 
please call Dr___________________    at 
______________. 
 
Before you turn to the next page, please answer these 
questions: 
 
DID ANYTHING HAPPEN TO YOU THIS WEEK THAT GAVE YOU MORE 
PAIN?      ___NO   ___YES.     IF ‗YES‘ PLEASE WRITE DOWN WHAT 
HAPPENED. 
 
 
 
 
 
 
 
 
 
DID  YOU  HAVE  BAD  EFFECTS  FROM  THE  DRUGS  DURING  THIS  
WEEK? 
IF YOU DID, PLEASE WRITE DOWN WHAT THEY WERE. 
 
 
 
 
APPENDIX B: PAIN DIARY WEEK 1 (BACK) 
 
Patient Name (Please Print) _____________________________________________ 
 
Telephone:    Home: ____________________     Work ________________________ 
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APPENDIX B: PAIN DIARY WEEK 6 (BACK) 
 
 
                                                 PAIN  SCORE 
 
              ___________________________________________________ 
              0       1       2        3        4        5        6        7        8        9       10 
   I HAVE                                                                                                    THIS IS THE  
NO PAIN                                                                                                    WORST PAIN 
                                                                                                                   I EVER HAD 
 
 
DATE COMPLETED ___________________________     
 
After you complete this page, please bring it with you to your weekly visit at the doctor’s office.  
 
 
Thank you for joining our important study. 
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oxycodone or 
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acetaminophen 
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take today? 
 
 
What was 
your pain 
score this 
morning? 
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your pain 
score 
tonight? 
 
How many 
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movements 
did you have 
today? 
Day 1: 
 
 
     
      
Day 2: 
 
 
     
      
Day 3: 
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Day 5: 
 
 
     
      
Day 6: 
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APPENDIX C: MINI MENTAL STATE EXAMINATION QUESTIONNAIRE 
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APPENDIX C: MINI MENTAL STATE EXAMINATION QUESTIONNAIRE 
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APPENDIX D: PATIENT STUDY SCHEDULE 
 
    
  
 
 
Memantine 
 
 
 
Pain 
 and 
 Medication 
Diary 
PART 1 
 
 
Week 1 None Daily 
   
Week 2 None Daily 
    
PART 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Week 3 
 
5 mg Memantine  AM 
- - - - - - - - - - - - - - - 
Nothing  PM 
Daily 
 
   
Week 4 
 
5 mg Memantine  AM 
+ 
5 mg memantine  PM 
Daily 
 
   
Week 5 
 
10 mg Memantine  AM 
+ 
5 mg memantine  PM 
Daily 
 
   
Week 6 
 
10 mg Memantine  AM 
+ 
10 mg memantine  PM 
Daily 
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